Elevation Insights™ | Pfizer IP/Patent Expirations

© Elevation Insights™ 2012-2014. All Rights Reserved.A Chirala Holdings™ Subsidiary & partner of Crescendus™ 1

Elevation Insights™

Pharmaceuticals & Biotechnology IntelligencePfizer IP/Patent Expirations

PFIZERIP/ PATENTEXPIRATIONS



202820252029Xalkori 202620262026Prevnar 13(8) 202620262023Eliquis(7) 202420212021Sutent 2025N/A(6)2020Xeljanz 202520202020Inlyta 202220212020Chantix N/A(5)20192019Bosulif 20222014(4)2018Lyrica 201920162015Zyvox 201920142014(3)Celebrex 20152015N/AEnbrel(2) 2013(1)20132012(1)ViagraJapan

Basic Product PatentExpiration Year

MajorEU Basic Product P

atent ExpirationYear

U.S. Basic Product PatentExpiration YearDrug

Major Drug Patent Expirations

Source: Pfizer 2013 10K SEC Filings



(1) In addition to the basic product patent covering Viagra, which expired in 2012, it is covered by a U.S.method-of-treatment patent which, including the six-month pediatric exclusivity period associated withRevatio, which has the same active ingredient as Viagra, expires in 2020. However, as a result of a patentlitigation settlement, Teva Pharmaceuticals USA, Inc. will be allowed to launch a generic version of Viagrain the U.S. in December 2017, or earlier under certain circumstances. The corresponding method-of-treatment patent covering Viagra in Japan expires in May 2014.(2) Pfizer does not market Enbrel in the U.S. For additional information, see the Overview of Our Performance,Operating Environment, Strategy and Outlook—Our Operating Environment—Intellectual Property Rightsand Collaboration/Licensing Rights section of the MD&A in our 2013 Financial Report. In other markets,biosimilar competition will depend, to a significant extent, on the timing and implementation ofregulations governing the development and approval of biosimilar products.(3) We obtained a reissue patent in the U.S. on March 5, 2013 covering the approved uses of Celebrex. Thereissue patent expires on December 2, 2015. This patent is presently the subject of litigation betweenPfizer and several generic companies.(4) For Lyrica, regulatory exclusivity in the EU extends until 2014.(5) Bosulif is not approved in Japan.(6) Xeljanz is not approved in the EU.

Footnotes to Major Drug Patent Expirations




(7) Eliquis was developed and is being commercialized in collaboration with BMS.(8) Prevnar 13 may eventually face competition in the form of alternative 13-valent and next-generationpneumococcal conjugate vaccines.

Footnotes to Major Drug Patent Expirations



Elevation Insights™ Healthcare Expertise

Pharmaceuticals, Generics,BiotechnologyDrugs, Biomarkers, Biosimilars, VaccinesDiscovery, DevelopmentClinical Trials, Data ManagementRegulatory Filings, IP ChallengesOutcomes Studies/ReimbursementMedical Devices & DiagnosticsClass I, II, III, Radiation EmittingIn-Vivo/In-VitroCompanion DiagnosticsConsumables, SuppliesBiomarkers

Life SciencesScientific/Analytical Instruments (LC-MS, MS, GC,XRD, IR, Optical Microscopy, FTIR, Raman, NMR, SPR,Fluorescence Specroscopy/Microscopy, AFM, HTSAssays, Screening systems)Reagents (e.g. antibodies, peptides, nucleic acids,signal labels)Enabling Technologies (Genomics, Proteomics,Glycomics, Systems Biology)Healthcare InformationTechnologyEHR, EMRTrial/Patient WorkflowsInformatics (Clinical, Chem, Bio, Lab)BiostatisticsHIPAA



Contact us if you need help with Pharma & Biotech Intelligence & Insights.Contact Information

Telephone:1-(865)-332-0942Email:[email protected]:www.elevationinsights.com

Elevation Insights™ | Pfizer IP/Patent Expirations

Health & Medicine

Transcript of Elevation Insights™ | Pfizer IP/Patent Expirations